Ionis, Ribo in RNA-Targeted Drug Alliance

Ionis Pharmaceuticals, Inc. has entered a collaboration and license agreement with Suzhou Ribo Life Science Co. to develop and commercialize RNA-targeted therapeutics in China. Ionis granted Ribo a license to commercialize two Ionis Generation 2+ antisense drugs in metabolic disease and cancer and an option to license a third Generation 2+ antisense drug. Ribo will be responsible for the research and drug discovery program to identify drugs that utilize Ionis' ssRNAi technology. Ionis will receive an undisclosed up-front payment and equity in Ribo. Ionis retains the rights to develop and commercialize ssRNAi technology and all drugs under the collaboration outside of China.

Following the identification of a development candidate, Ribo may exercise its option to license each drug by paying Ionis a license fee. For each drug that Ribo licenses, Ribo will be responsible for all development and commercialization activities and costs in China. Ionis is eligible to receive development, regulatory and commercial milestone payments, as well as royalties on sales.

"The need for new medicines in China is growing rapidly, especially for metabolic diseases and certain genetically-defined cancers," said Brett Monia, senior vice president of drug discovery and franchise leader for oncology and rare diseases at Ionis Pharmaceuticals. "Ribo is the ideal partner for us in China. Ribo has made excellent progress in its RNAi therapeutic programs and we believe we will benefit from their drug development and regulatory expertise in China. We believe that our partnership with Ribo maximizes the value of our drugs in this collaboration by leveraging the clinical data generated in China to support the overall global development plan for each drug."

"We are committed to advancing new RNA-targeted therapeutics, like RNAi and antisense, to patients with high unmet medical need in China," said Liang Zicai, founder and Chairman of Ribo. "Ionis has made significant breakthroughs showing that chemically modified single-stranded oligonucleotides can activate the RNAi pathway. We believe that this work is the foundation for a robust drug discovery platform that takes advantage of using single-stranded RNA-like antisense drugs that harness the power of the RNAi pathway. We are excited by the opportunity to contribute our expertise and resources to advancing this promising technology."